The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Drug–target residence time: critical information for lead optimization
Open accessAbstract
Summary of recent advances Failure due to poor in vivo efficacy is a primary contributor to attrition during the development of new chemotherapeutics. Lead optimization programs that in their quest for efficacy focus solely on improving the affinity of drug-target binding are flawed, since this approach ignores the fluctuations in drug concentration that occur in vivo. Instead the lifetime of the drug-target complex must also be considered, since drugs only act when they are bound to their targets. Consequently, to improve the correlation between the in vitro and in vivo activity of drugs, measurements of drug-target residence time must be incorporated into the drug discovery process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 3×
“For the histone deacetylase inhibitor pimelic diphenylamide 106 [6,7], the percent target occupancy has been plotted as a function of time using a drug–target complex half-life (t1/2) of 8 h (the koff value for this inhibitor is 0.”
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Copeland, R. A. (2005) · PubMed · Cited by 1,092
The Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
Tummino, P. J., & Copeland, R. A. (2008) · Biochemistry · doi:10.1021/bi8002023 · Cited by 544
Biochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
Rawat, R., Whitty, A., & Tonge, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2235848100 · Cited by 330
Self-citationInhibitors of FabI, an Enzyme Drug Target in the Bacterial Fatty Acid Biosynthesis Pathway
Lu, H., & Tonge, P. J. (2008) · Accounts of Chemical Research · doi:10.1021/ar700156e · Cited by 254
Self-citationStructural basis and mechanism of enoyl reductase inhibition by triclosan
Stewart, M. J., Parikh, S., Xiao, G., Tonge, P. J., & Kisker, C. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.2907 · Cited by 225
Self-citation
Cited by
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Sulfur(VI) Fluoride Exchange (SuFEx): Another Good Reaction for Click Chemistry
Dong, J., Krasnova, L., Finn, M. G., & Sharpless, K. B. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309399 · Cited by 1,390
Role of Molecular Dynamics and Related Methods in Drug Discovery
De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,297
Pathway and mechanism of drug binding to G-protein-coupled receptors
Dror, R. O., Pan, A. C., Arlow, D. H., Borhani, D. W., Maragakis, P., Shan, Y., Xu, H., & Shaw, D. E. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104614108 · Cited by 730
The drug–target residence time model: a 10-year retrospective
Copeland, R. A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.18 · Cited by 722
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor
Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R.-F., Hu, J., Kern, G., Walkup, G. K., & Fisher, S. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205073109 · Cited by 545
Prolonged and tunable residence time using reversible covalent kinase inhibitors
Bradshaw, J. M., McFarland, J. M., Paavilainen, V. O., Bisconte, A., Tam, D., Phan, V. T., Romanov, S., Finkle, D., Shu, J., Patel, V., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1817 · Cited by 422
Molecular determinants of drug–receptor binding kinetics
Pan, A. C., Borhani, D. W., Dror, R. O., & Shaw, D. E. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.02.007 · Cited by 373
Sun, H., Duan, L., Chen, F., Liu, H., Wang, Z., Pan, P., Zhu, F., Zhang, J. Z. H., & Hou, T. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp07623a · Cited by 372
New agents for the treatment of drug-resistant Mycobacterium tuberculosis
Hoagland, D. T., Liu, J., Lee, R. B., & Lee, R. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.026 · Cited by 328
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
Thermodynamics and Kinetics of Drug-Target Binding by Molecular Simulation
Decherchi, S., & Cavalli, A. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00534 · Cited by 301
Protein conformational flexibility modulates kinetics and thermodynamics of drug binding
Amaral, M., Kokh, D. B., Bomke, J., Wegener, A., Buchstaller, H. P., Eggenweiler, H. M., Matias, P., Sirrenberg, C., Wade, R. C., & Frech, M. (2017) · Nature Communications · doi:10.1038/s41467-017-02258-w · Cited by 291
Drug–Target Kinetics in Drug Discovery
Tonge, P. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00185 · Cited by 287
Self-citationIntegrating Molecular Docking and Molecular Dynamics Simulations
Santos, L. H. S., Ferreira, R. S., & Caffarena, E. R. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9752-7_2 · Cited by 285
Target engagement and drug residence time can be observed in living cells with BRET
Robers, M. B., Dart, M. L., Woodroofe, C. C., Zimprich, C. A., Kirkland, T. A., Machleidt, T., Kupcho, K. R., Levin, S., Hartnett, J. R., Zimmerman, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms10091 · Cited by 274
Targeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180
Atomic resolution mechanism of ligand binding to a solvent inaccessible cavity in T4 lysozyme
(2018) · doi:10.1371/journal.pcbi.1006180 · Cited by 77
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Neumann, L., von König, K., & Ullmann, D. (2011) · Methods in Enzymology · doi:10.1016/b978-0-12-381274-2.00012-1 · Cited by 51
Metadata
- Authors
- Lu, H., & Tonge, P. J.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2010-08
- Volume
- 14
- Issue
- 4
- Pages
- 467-474
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2040680919
- Cited by
- 432
- References
- 32
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.